/ 2 items

#AKRO↓

Featured/ AKRO/ 10/09/2025 · 8:28 AM

Novo Nordisk Acquires Akero Therapeutics for $5.2 Billion, Securing Key MASH Treatment EFX

Novo Nordisk has agreed to acquire clinical-stage Akero Therapeutics for up to $5.2 billion to integrate efruxifermin (EFX), a promising late-stage treatment for MASH, complementing Novo Nordisk's leadership in cardiometabolic disease.

Featured/ ETNB/ 09/19/2025 · 8:35 AM

Pharma Giant Roche Buys 89bio for up to $3.5 Billion to Fight Fatty Liver Disease

Pharma giant Roche bought 89bio for up to $3.5B. The focus is pegozafermin, a promising drug for treating MASH (severe fatty liver disease). This deal positions Roche to transform care in metabolic diseases. Shares of 89bio surged 85% on Thursday.